@article{MTMT:34836460,
	title = {An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease},
	url = {https://m2.mtmt.hu/api/publication/34836460},
	author = {Zhang, Le and El-Shabrawi, Mortada and Baur, Louise A and Byrne, Christopher D and Targher, Giovanni and Kehar, Mohit and Porta, Gilda and Lee, Way Seah and Lefere, Sander and Turan, Serap and Alisi, Anna and Weiss, Ram and Faienza, Maria Felicia and Ashraf, Ambika and Sundaram, Shikha S and Srivastava, Anshu and De Bruyne, Ruth and Kang, Yunkoo and Bacopoulou, Flora and Zhou, Yong-Hai and Darma, Andy and Lupsor-Platon, Monica and Hamaguchi, Masahide and Misra, Anoop and Méndez-Sánchez, Nahum and Ng, Nicholas Beng Hui and Marcus, Claude and Staiano, Amanda E and Waheed, Nadia and Alqahtani, Saleh A and Giannini, Cosimo and Ocama, Ponsiano and Nguyen, Mindie H and Arias-Loste, Maria Teresa and Ahmed, Mohamed Rabea and Sebastiani, Giada and Poovorawan, Yong and Al Mahtab, Mamun and Pericàs, Juan M and Reverbel da Silveira, Themis and Hegyi, Péter and Azaz, Amer and Isa, Hasan M and Lertudomphonwanit, Chatmanee and Farrag, Mona Issa and Nugud, Ahmed Abd Alwahab and Du, Hong-Wei and Qi, Ke-Min and Mouane, Nezha and Cheng, Xin-Ran and Al Lawati, Tawfiq and Fagundes, Eleonora D T and Ghazinyan, Hasmik and Hadjipanayis, Adamos and Fan, Jian-Gao and Gimiga, Nicoleta and Kamal, Naglaa M and Ștefănescu, Gabriela and Hong, Li and Diaconescu, Smaranda and Li, Ming and George, Jacob and Zheng, Ming-Hua},
	doi = {10.1016/j.medj.2024.03.017},
	journal-iso = {Med},
	journal = {Med},
	unique-id = {34836460},
	issn = {2666-6340},
	abstract = {Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in children and adolescents, particularly those with obesity. NAFLD is considered a hepatic manifestation of the metabolic syndrome due to its close associations with abdominal obesity, insulin resistance, and atherogenic dyslipidemia. Experts have proposed an alternative terminology, metabolic dysfunction-associated fatty liver disease (MAFLD), to better reflect its pathophysiology. This study aimed to develop consensus statements and recommendations for pediatric MAFLD through collaboration among international experts.A group of 65 experts from 35 countries and six continents, including pediatricians, hepatologists, and endocrinologists, participated in a consensus development process. The process encompassed various aspects of pediatric MAFLD, including epidemiology, mechanisms, screening, and management.In round 1, we received 65 surveys from 35 countries and analyzed these results, which informed us that 73.3% of respondents agreed with 20 draft statements while 23.8% agreed somewhat. The mean percentage of agreement or somewhat agreement increased to 80.85% and 15.75%, respectively, in round 2. The final statements covered a wide range of topics related to epidemiology, pathophysiology, and strategies for screening and managing pediatric MAFLD.The consensus statements and recommendations developed by an international expert panel serve to optimize clinical outcomes and improve the quality of life for children and adolescents with MAFLD. These findings emphasize the need for standardized approaches in diagnosing and treating pediatric MAFLD.This work was funded by the National Natural Science Foundation of China (82070588, 82370577), the National Key R&D Program of China (2023YFA1800801), National High Level Hospital Clinical Research Funding (2022-PUMCH-C-014), the Wuxi Taihu Talent Plan (DJTD202106), and the Medical Key Discipline Program of Wuxi Health Commission (ZDXK2021007).},
	keywords = {CHILDREN; Consensus; Adolescents; Non-Alcoholic Fatty Liver Disease; MAFLD; Metabolic dysfunction-associated fatty liver disease; Translation to population health; MASLD},
	year = {2024},
	orcid-numbers = {Hegyi, Péter/0000-0003-0399-7259}
}

@article{MTMT:34833996,
	title = {A Systematic Review and Meta-Analysis of microRNA Profiling Studies in Chronic Kidney Diseases},
	url = {https://m2.mtmt.hu/api/publication/34833996},
	author = {Gantsetseg, Garmaa and Bunduc, Stefania and Kói, Tamás and Hegyi, Péter and Csupor, Dezső and Dariimaa, Ganbat and Dembrovszky, Fanni and Meznerics, Fanni Adél and Ailar, Nasirzadeh and Cristina, Barbagallo and Kökény, Gábor},
	doi = {10.3390/ncrna10030030},
	journal-iso = {NON-CODING RNA},
	journal = {NON-CODING RNA},
	volume = {10},
	unique-id = {34833996},
	keywords = {[Meta-analysis]},
	year = {2024},
	eissn = {2311-553X},
	orcid-numbers = {Gantsetseg, Garmaa/0000-0001-9631-8635; Hegyi, Péter/0000-0003-0399-7259; Csupor, Dezső/0000-0002-4088-3333; Dembrovszky, Fanni/0000-0001-6953-3591; Kökény, Gábor/0000-0002-0345-6914}
}

@article{MTMT:34825011,
	title = {Imiquimod Is Effective in Reducing Cervical Intraepithelial Neoplasia : A Systematic Review and Meta-Analysis},
	url = {https://m2.mtmt.hu/api/publication/34825011},
	author = {Hamar, Balázs and Teutsch, Brigitta and Hoffmann, Eszter and Hegyi, Péter and Harnos, Andrea and Nyirády, Péter and Hunka, Zsombor Rezső and Ács, Nándor and Bánhidy, Ferenc and Melczer, Zsolt},
	doi = {10.3390/cancers16081610},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {16},
	unique-id = {34825011},
	abstract = {Topical Imiquimod is an immune response modifier approved for the off-label use of vulvar intraepithelial neoplasia. We conducted this systematic review and meta-analysis to investigate the efficacy and safety of Imiquimod in treating cervical intraepithelial neoplasia (CIN) and human papillomavirus (HPV)-positive patients.The study was prospectively registered (CRD420222870) and involved a comprehensive systematic search of five medical databases on 10 October 2022. We included articles that assessed the use of Imiquimod in cervical dysplasia and HPV-positive patients. Pooled proportions, risk ratios (RRs), and corresponding 95% confidence intervals (CIs) were calculated using a random effects model to generate summary estimates. Statistical heterogeneity was assessed using I2 tested by the Cochran Q tests.Eight articles reported on 398 patients who received Imiquimod out of 672 patients. Among CIN-2-3 patients, we observed a pooled regression rate of 61% (CI: 0.46-0.75; I2: 77%). When compared, Imiquimod was inferior to conization (RR: 0.62; CI: 0.42-0.92; I2: 64%). The HPV clearance rate in women who completed Imiquimod treatment was 60% (CI: 0.31-0.81; I2: 57%). The majority of side effects reported were mild to moderate in severity.Our findings indicate that topical Imiquimod is safe and effective in reducing cervical intraepithelial neoplasia and promoting HPV clearance. However, it was found to be inferior compared to conization. Imiquimod could be considered a potential medication for high-grade CIN patients and should be incorporated into guidelines for treating cervical dysplasia.},
	keywords = {imiquimod; HPV; Cervical cancer; [Meta-analysis]; gynecologic cancer risk reduction},
	year = {2024},
	eissn = {2072-6694},
	orcid-numbers = {Teutsch, Brigitta/0000-0002-9530-7886; Hegyi, Péter/0000-0003-0399-7259; Nyirády, Péter/0000-0002-7037-4919; Hunka, Zsombor Rezső/0000-0003-1824-2254; Ács, Nándor/0000-0002-1919-1869; Bánhidy, Ferenc/0000-0001-8910-1964; Melczer, Zsolt/0000-0002-5287-8064}
}

@article{MTMT:34824534,
	title = {Predictive value of magnetic resonance imaging diffusion parameters using artificial intelligence in low-and intermediate-risk prostate cancer patients treated with stereotactic ablative radiotherapy: A pilot study},
	url = {https://m2.mtmt.hu/api/publication/34824534},
	author = {Kedves, András and Akay, M. and Akay, Y. and Kisiván, K. and Glavák, C. and Miovecz, Ádám and Schiffer, Ádám and Kisander, Zsolt and Lőrincz, Aba Tamás and Szőke, András and Sánta, B. and Freihat, Omar and Sipos, Dávid and Kovács, Árpád and Lakosi, Ferenc},
	doi = {10.1016/j.radi.2024.03.015},
	journal-iso = {RADIOGRAPHY},
	journal = {RADIOGRAPHY},
	volume = {30},
	unique-id = {34824534},
	issn = {1078-8174},
	year = {2024},
	pages = {986-994},
	orcid-numbers = {Miovecz, Ádám/0000-0001-7329-3252; Schiffer, Ádám/0000-0002-0769-2375; Lőrincz, Aba Tamás/0000-0002-6705-3292; Sipos, Dávid/0000-0001-9615-1740; Kovács, Árpád/0000-0002-8469-5764}
}

@{MTMT:34823724,
	title = {Termoneutralitás},
	url = {https://m2.mtmt.hu/api/publication/34823724},
	author = {Garami, András},
	booktitle = {Súlyos baleseti agysérültek ellátása},
	unique-id = {34823724},
	year = {2024},
	pages = {172-173},
	orcid-numbers = {Garami, András/0000-0003-2493-0571}
}

@{MTMT:34823695,
	title = {Hőszabályozás},
	url = {https://m2.mtmt.hu/api/publication/34823695},
	author = {Garami, András},
	booktitle = {Súlyos baleseti agysérültek ellátása},
	unique-id = {34823695},
	year = {2024},
	pages = {51-54},
	orcid-numbers = {Garami, András/0000-0003-2493-0571}
}

@article{MTMT:34804165,
	title = {Ammonium chloride-induced hypothermia is attenuated by transient receptor potential channel vanilloid-1, but augmented by ankyrin-1 in rodents},
	url = {https://m2.mtmt.hu/api/publication/34804165},
	author = {Rumbus, Zoltán and Fekete, Kata and Kelava, Leonardo and Gardos, Bibor and Klonfar, Krisztian and Kéringer, Patrik and Pintér, Erika and Pákai, Eszter and Garami, András},
	doi = {10.1016/j.lfs.2024.122633},
	journal-iso = {LIFE SCI},
	journal = {LIFE SCIENCES},
	volume = {346},
	unique-id = {34804165},
	issn = {0024-3205},
	abstract = {Systemic administration of ammonium chloride (NH4Cl), an acidifying agent used in human patients and experimental conditions, causes hypothermia in mice, however, the mechanisms of the thermoregulatory response to NH4Cl and whether it develops in other species remained unknown.We studied body temperature (Tb) changes in rats and mice induced by intraperitoneal administration of NH4Cl after blockade of transient receptor potential vanilloid-1 (TRPV1) or ankyrin-1 (TRPA1) channels.In rats, NH4Cl decreased Tb by 0.4-0.8°C (p < 0.05). The NH4Cl-induced hypothermia also developed in Trpv1 knockout (Trpv1-/-) and wild-type (Trpv1+/+) mice, however, the Tb drop was exaggerated in Trpv1-/- mice compared to Trpv1+/+ controls with maximal decreases of 4.0 vs. 2.1°C, respectively (p < 0.05). Pharmacological blockade of TRPV1 channels with AMG 517 augmented the hypothermic response to NH4Cl in genetically unmodified mice and rats (p < 0.05 for both). In contrast, when NH4Cl was infused to mice genetically lacking the TRPA1 channel, the hypothermic response was significantly attenuated compared to wild-type controls with maximal mean Tb difference of 1.0°C between the genotypes (p = 0.008). Pretreatment of rats with a TRPA1 antagonist (A967079) also attenuated the NH4Cl-induced Tb drop with a maximal difference of 0.7°C between the pretreatment groups (p = 0.003).TRPV1 channels limit, whereas TRPA1 channels exaggerate the development of NH4Cl-induced hypothermia in rats and mice, but other mechanisms are also involved. Our results warrant for regular Tb control and careful consideration of NH4Cl treatment in patients with TRPA1 and TRPV1 channel dysfunctions.},
	keywords = {THERMOREGULATION; TRPV1; hypothermia; TRPA1; thermophysiology; NH(4)Cl},
	year = {2024},
	eissn = {1879-0631},
	orcid-numbers = {Pintér, Erika/0000-0001-9898-632X; Garami, András/0000-0003-2493-0571}
}

@article{MTMT:34803211,
	title = {Real-world data on sequential therapy in moderate-to-severe UC: Unveiling second-line strategies after anti-TNF failure},
	url = {https://m2.mtmt.hu/api/publication/34803211},
	author = {Farkas, B. and Borsos, M. and Resal, T. and Bacsur, P. and Szepes, Z. and Savarino, E. V. and Bertin, L. and Limdi, J. K. and Sethi-Arora, K. and Miheller, P. and Vilmos, F. and Castiglione, F. and Bonacci, L. and Lukas, M. and Maharshak, N. and Berman, G. and Krznaric, Z. and Wetwittayakhlang, P. and Lakatos, P. L. and Seidelin, J. B. and Attauabi, M. and Michalopoulos, G. and Ribaldone, D. G. and Kagramanova, A. and Chashkova, E. and Sarlós, Patrícia and Saibeni, S. and Shitrit, A. B. G. and Molnar, T. and Farkas, K.},
	journal-iso = {J CROHNS COLITIS},
	journal = {JOURNAL OF CROHNS & COLITIS},
	volume = {18},
	unique-id = {34803211},
	issn = {1873-9946},
	year = {2024},
	eissn = {1876-4479},
	pages = {I1828-I1829},
	orcid-numbers = {Sarlós, Patrícia/0000-0002-5086-9455}
}

@article{MTMT:34801787,
	title = {The effect of nicotine-containing products on peri-implant tissues : A systematic review and network meta-analysis},
	url = {https://m2.mtmt.hu/api/publication/34801787},
	author = {Vámos, Orsolya and Komora, Péter and Gede, Noémi and Hegyi, Péter and Kelemen, Kata and Varga, Gábor and Mikulás, Krisztina Ágnes and Kerémi, Beáta and Kispélyi, Ida Barbara},
	doi = {10.1093/ntr/ntae085},
	journal-iso = {NICOTINE TOB RES},
	journal = {NICOTINE AND TOBACCO RESEARCH},
	unique-id = {34801787},
	issn = {1462-2203},
	abstract = {Smokers have a higher chance of developing peri-implant diseases and are therefore considered an at-risk population. Our aim was to compare peri-implant characteristics in users of electronic cigarettes (EC), waterpipes (WP), cigarettes (CS), smokeless tobacco (ST), and non-smokers (non-users of any nicotine and tobacco product; NS).A systematic search of four electronic databases (PubMed, EMBASE, Web of Science, CENTRAL) was performed until April 2023, restricted to English language. Thirty-nine observational studies were included in the qualitative synthesis, of which 32 studies were included in a Bayesian network meta-analysis. Using a predesigned form, two researchers independently collected data about marginal bone loss (MBL), probing pocket depth (PPD), plaque index (PI), bleeding on probing (BOP), modified plaque index (mPI), probing pocket depth > 4mm (PPD>4), gingival index (GI), peri-implant sulcular fluid (PISF) volume, and TNF-α and IL-1β levels. QUIPS and CINeMA were used to evaluate the risk of bias and certainty of evidence.NS had the smallest MBL. Most nicotine-containing product users had significantly higher MBL (CS, MD:1.34 CrI: 0.85, 1.79; WP, MD:1.58 CrI: 0.84, 2.35; ST, MD:2.53, CrI: 1.20, 3.87) than NS. EC did not show significant difference compared to NS (MD:0.52 CrI: -0.33, 1.36). In secondary outcomes NS were ranked in first place. Subset analysis based on smoking habit, implant duration, and maintenance control revealed no differences in ranking probability.Most nicotine-containing product users presented worse peri-implant parameters compared to non-smokers, while EC users did not show significant differences to NS in many outcomes.Alternative nicotine-containing products are gaining popularity and are often considered less harmful by the general public compared to traditional cigarettes. This is the first network meta-analysis comparing users of four nicotine-containing products and non-smokers. This study shows that CS, WP and ST have a detrimental effect on the overall health of peri-implant tissues. EC users also presented inferior parameters compared to NS, however, the difference was not significant in many outcomes. It is essential to educate patients who are using nicotine-containing products, and to provide proper maintenance and appropriate cessation support. Well-designed multi-armed studies are needed for direct comparison of different products, including heated tobacco products. Greater transparency of confounding factors is needed regarding smoking habit and oral hygiene.},
	keywords = {tobacco; cigarette smoking; smokeless tobacco; Peri-implantitis; E-cigarette; waterpipe; peri-implant parameters; [Meta-analysis]},
	year = {2024},
	eissn = {1469-994X},
	orcid-numbers = {Komora, Péter/0000-0002-1436-7781; Hegyi, Péter/0000-0003-0399-7259; Varga, Gábor/0000-0002-5506-8198; Mikulás, Krisztina Ágnes/0000-0002-0259-9761; Kerémi, Beáta/0000-0003-4000-9440; Kispélyi, Ida Barbara/0000-0002-0530-0905}
}

@article{MTMT:34801778,
	title = {Estimation of the incidence of urachal cancer : A systematic review and meta-analysis of registry-based studies},
	url = {https://m2.mtmt.hu/api/publication/34801778},
	author = {Olah, Csilla and Kubik, András and Mátrai, Péter and Engh, Marie Anne and Barna, Viktória and Hegyi, Péter and Reis, Henning and Nyirády, Péter and Szarvas, Tibor},
	doi = {10.1016/j.urolonc.2024.03.011},
	journal-iso = {UROL ONCOL SEMIN ORI INV},
	journal = {UROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS},
	unique-id = {34801778},
	issn = {1078-1439},
	abstract = {Urachal cancer (UrC) is a rare disease with limited availability of representative incidence and clinical data. Although, the prevalence is accounting for less than 1% of bladder tumors, the 5-year survival rate is around only 50% for patients with resectable tumors, and even worse for patients with metastatic disease. Due to the lack of comprehensive prospective studies, our current knowledge of UrC is still limited.The present study aimed to summarize the available registry-based studies with unselected UrC patients to evaluate its incidence and clinicopathological characteristics.We conducted a systematic literature search of registry-based UrC publications on the 15th of May 2023 in 5 databases, which identified 4,748 publications. After duplicate removal and selection by 2 independent investigators, 6 publications proved to be appropriate for the final meta-analysis. Estimated incidence and clinicopathological parameters were extracted.Estimated incidence ranged between 0.022 and 0.060/ 100.000 person-years, with the highest occurrence in Japan and the lowest in Canada, while the random effect model calculated an overall incidence rate of 0.04 (95%CI: 0.03-0.05) 100.000 person-years. The median age at first diagnosis was 60 years (range: 58-64). The female to male ratio was 2:3. Lymph node or distant metastases were present in 9% and 14% of patients. The predominant tumour type was adenocarcinoma (86%) followed by urothelial carcinoma (12%) and squamous cell carcinoma (2%). The 5-year survival rate was 51.0% with 95%CI: 45.2-57.4.Our study provides an up-to-date comparison of estimated incidence rates between 6 countries of 3 continents based on rigorously selected registry-based studies. The results suggest low incidence rates for UrC with considerable geographic differences. The present meta-analysis provides unbiased registry-based data on the incidence, clinicopathological parameters and survival of UrC.},
	keywords = {Incidence; EPIDEMIOLOGY; REGISTRY; Adenocarcinoma; bladder cancer; urachal cancer; Urachus carcinoma; [Meta-analysis]},
	year = {2024},
	eissn = {1873-2496},
	orcid-numbers = {Kubik, András/0000-0001-6901-9701; Engh, Marie Anne/0000-0003-4269-5130; Hegyi, Péter/0000-0003-0399-7259; Nyirády, Péter/0000-0002-7037-4919; Szarvas, Tibor/0000-0002-6321-0799}
}